Additionally, anti-PDL1, Atezolizumab, when combined with bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic NSCLC [158]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.